| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2012PLoSO...741140C |
| P356 | DOI | 10.1371/JOURNAL.PONE.0041140 |
| P932 | PMC publication ID | 3399789 |
| P698 | PubMed publication ID | 22815943 |
| P5875 | ResearchGate publication ID | 229427945 |
| P50 | author | Catherine Verfaillie | Q615166 |
| P2093 | author name string | Feng Chen | |
| Jie Yu | |||
| Marlein Miranda Cona | |||
| Raymond Oyen | |||
| Yansheng Jiang | |||
| Yicheng Ni | |||
| Yuanbo Feng | |||
| Junjie Li | |||
| Bart De Geest | |||
| Yingmei Feng | |||
| Guy Marchal | |||
| Huaijun Wang | |||
| Frederik De Keyzer | |||
| Kaier Zheng | |||
| P2860 | cites work | Thalidomide is an inhibitor of angiogenesis | Q24563363 |
| Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis | Q28222601 | ||
| Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy | Q29547379 | ||
| Osteogenic sarcoma: noninvasive in vivo assessment of tumor necrosis with diffusion-weighted MR imaging | Q32153909 | ||
| Thalidomide in solid tumours: the resurrection of an old drug | Q33208578 | ||
| Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. | Q33211653 | ||
| Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression | Q33265941 | ||
| Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia | Q34021937 | ||
| A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. | Q34046046 | ||
| The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents | Q34122191 | ||
| Multiplexed imaging in cancer diagnosis: applications and future advances | Q36143279 | ||
| Disrupting tumour blood vessels | Q36146900 | ||
| Repopulation of cancer cells during therapy: an important cause of treatment failure | Q36167592 | ||
| Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging | Q36739621 | ||
| Antivascular actions of microtubule-binding drugs | Q37349697 | ||
| Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. | Q37378187 | ||
| Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies | Q37534993 | ||
| Liver tumor model with implanted rhabdomyosarcoma in rats: MR imaging, microangiography, and histopathologic analysis | Q39748901 | ||
| A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. | Q40200899 | ||
| Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. | Q40228810 | ||
| Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. | Q40479307 | ||
| ZD6126: a novel small molecule vascular targeting agent | Q40686415 | ||
| High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis | Q41209024 | ||
| Modeling tracer kinetics in dynamic Gd-DTPA MR imaging | Q41352795 | ||
| Endothelial-cell proliferation in experimental tumours | Q41502842 | ||
| Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration | Q41537813 | ||
| Targeted therapies: Thalidomide in lung cancer therapy-what have we learned? | Q43146801 | ||
| Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors | Q45133701 | ||
| Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology | Q46228470 | ||
| Human ApoA-I transfer attenuates transplant arteriosclerosis via enhanced incorporation of bone marrow-derived endothelial progenitor cells | Q46862751 | ||
| Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas | Q48088826 | ||
| Diffusion weighted imaging in small rodents using clinical MRI scanners. | Q53466991 | ||
| Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature | Q73352832 | ||
| Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer | Q80165576 | ||
| Multiparametric imaging of tumor response to therapy | Q84591883 | ||
| Cancer models-multiparametric applications of clinical MRI in rodent hepatic tumor model | Q84847970 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | angiogenesis inhibitor | Q574834 |
| P304 | page(s) | e41140 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI | |
| P478 | volume | 7 |
| Q34849516 | Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model |
| Q36613314 | Diverse responses to vascular disrupting agent combretastatin a4 phosphate: a comparative study in rats with hepatic and subcutaneous tumor allografts using MRI biomarkers, microangiography, and histopathology |
| Q35077659 | Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging noninvasive evaluation of vascular disrupting treatment on rabbit liver tumors |
| Q41549134 | Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P. |
| Q50041830 | Monitoring tumor response to the vascular disrupting agent CKD-516 in a rabbit VX2 intramuscular tumor model using PET/MRI: Simultaneous evaluation of vascular and metabolic parameters |
| Q89551846 | Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation |
| Q37408968 | Separate calculation of DW-MRI in assessing therapeutic effect in liver tumors in rats |
| Q36609881 | Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications |
| Q38259982 | Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference |
| Q26774355 | Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions |
Search more.